{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:50:55Z","timestamp":1789098655190,"version":"build-2803163510"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.addr.2023.114874","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:35:39Z","timestamp":1684467339000},"page":"114874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["New antifungal strategies: Drug combination and co-delivery"],"prefix":"10.1016","volume":"198","author":[{"given":"Ping","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Tancer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-1468","authenticated-orcid":false,"given":"Chaoyang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojian","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2023.114874_b0005","doi-asserted-by":"crossref","first-page":"165rv113","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.114874_b0010","unstructured":"WHO, WHO fungal priority pathogens list to guide research, development and public health action, 2022."},{"key":"10.1016\/j.addr.2023.114874_b0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The antifungal pipeline: a reality check","volume":"16","author":"Perfect","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.114874_b0020","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aap7999","article-title":"Worldwide emergence of resistance to antifungal drugs challenges human health and food security","volume":"360","author":"Fisher","year":"2018","journal-title":"Science\uff0c"},{"key":"10.1016\/j.addr.2023.114874_b0025","unstructured":"CDC, Antibiotic resistance threats in the United States, 2019."},{"key":"10.1016\/j.addr.2023.114874_b0030","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse effects associated with long-term administration of azole antifungal agents","volume":"79","author":"Benitez","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2023.114874_b0035","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/jac\/dkac352","article-title":"Liposomal amphotericin B-the present","volume":"77","author":"Maertens","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2023.114874_b0040","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: Fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2023.114874_b0045","doi-asserted-by":"crossref","first-page":"e00924","DOI":"10.1128\/AAC.00924-20","article-title":"Screening repurposing libraries for identification of drugs with novel antifungal activity","volume":"64","author":"Wall","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114874_b0050","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/21505594.2016.1197444","article-title":"Targeting Candida albicans filamentation for antifungal drug development","volume":"8","author":"Vila","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.addr.2023.114874_b0055","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.drudis.2022.04.021","article-title":"Repurposing and optimization of drugs for discovery of novel antifungals","volume":"27","author":"Donlin","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2023.114874_b0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","article-title":"Drug combinations: a strategy to extend the life of antibiotics in the 21st century","volume":"17","author":"Tyers","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2023.114874_b0065","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/21505594.2016.1196300","article-title":"Combinatorial strategies for combating invasive fungal infections","volume":"8","author":"Spitzer","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.addr.2023.114874_b0070","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41579-022-00700-5","article-title":"The physiology and genetics of bacterial responses to antibiotic combinations","volume":"20","author":"Roemhild","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2023.114874_b0075","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41579-021-00511-0","article-title":"Treatment strategies for cryptococcal infection: challenges, advances and future outlook","volume":"19","author":"Iyer","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2023.114874_b0080","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/cid\/ciu581","article-title":"Antifungal combination therapy for invasive aspergillosis","volume":"59","author":"Martin-Pena","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2023.114874_b0085","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11908-007-0069-1","article-title":"Combination antifungal therapy for the treatment of invasive yeast and mold infections","volume":"9","author":"Baddley","year":"2007","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.addr.2023.114874_b0090","doi-asserted-by":"crossref","first-page":"451","DOI":"10.14740\/jocmr2992w","article-title":"Combination antifungal therapy: A review of current data","volume":"9","author":"Campitelli","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.addr.2023.114874_b0095","doi-asserted-by":"crossref","first-page":"eabo2658","DOI":"10.1126\/sciadv.abo2658","article-title":"Amphotericin B assembles into seven-molecule ion channels: An NMR and molecular dynamics study","volume":"8","author":"Umegawa","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2023.114874_b0100","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1073\/pnas.1117280109","article-title":"Amphotericin primarily kills yeast by simply binding ergosterol","volume":"109","author":"Gray","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2023.114874_b0105","doi-asserted-by":"crossref","first-page":"2068109","DOI":"10.1080\/2162402X.2022.2068109","article-title":"Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade","volume":"11","author":"Kofla","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2023.114874_b0110","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1523\/JNEUROSCI.1797-14.2015","article-title":"Stimulation of monocytes, macrophages, and microglia by amphotericin B and macrophage colony-stimulating factor promotes remyelination","volume":"35","author":"Doring","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.addr.2023.114874_b0115","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.apsb.2021.04.010","article-title":"Delivery strategies of amphotericin B for invasive fungal infections","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2023.114874_b0120","article-title":"Amphotericin B and other polyenes-discovery, clinical use, mode of action and drug resistance","volume":"6","author":"Carolus","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.addr.2023.114874_b0125","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1586\/14787210.2015.1032939","article-title":"Azole antifungals: 35 years of invasive fungal infection management","volume":"13","author":"Allen","year":"2015","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.addr.2023.114874_b0130","doi-asserted-by":"crossref","first-page":"105807","DOI":"10.1016\/j.ijantimicag.2019.09.011","article-title":"Azole resistance mechanisms in Aspergillus: update and recent advances","volume":"55","author":"Perez-Cantero","year":"2020","journal-title":"Int. J. Antimicrob. Ag."},{"key":"10.1016\/j.addr.2023.114874_b0135","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cmi.2019.03.028","article-title":"Resistance of Candida to azoles and echinocandins worldwide","volume":"25","author":"Pristov","year":"2019","journal-title":"Clin. Microbiol. Infec."},{"key":"10.1016\/j.addr.2023.114874_b0140","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1128\/EC.3.6.1639-1652.2004","article-title":"TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2","volume":"3","author":"Coste","year":"2004","journal-title":"Eukaryot. Cell"},{"key":"10.1016\/j.addr.2023.114874_b0145","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1534\/genetics.105.054767","article-title":"A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans","volume":"172","author":"Coste","year":"2006","journal-title":"Genetics"},{"key":"10.1016\/j.addr.2023.114874_b0150","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1371\/journal.ppat.0030164","article-title":"The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans","volume":"3","author":"Morschhauser","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2023.114874_b0155","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cmi.2018.11.007","article-title":"Molecular mechanisms of azole resistance in Candida tropicalis isolates causing invasive candidiasis in China","volume":"25","author":"Fan","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.addr.2023.114874_b0160","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1126\/science.1128242","article-title":"Aneuploidy and isochromosome formation in drug-resistant Candida albicans","volume":"313","author":"Selmecki","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114874_b0165","doi-asserted-by":"crossref","first-page":"e1000848","DOI":"10.1371\/journal.ppat.1000848","article-title":"Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes","volume":"6","author":"Sionov","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2023.114874_b0170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00253-020-11022-y","article-title":"Echinocandins: structural diversity, biosynthesis, and development of antimycotics","volume":"105","author":"Huttel","year":"2021","journal-title":"Appl. Microbiol. Biot."},{"key":"10.1016\/j.addr.2023.114874_b0175","doi-asserted-by":"crossref","first-page":"S662","DOI":"10.1093\/cid\/civ739","article-title":"Antifungal-associated drug-induced cardiac disease","volume":"61","author":"Cleary","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2023.114874_b0180","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2023.114874_b0185","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1021\/acs.chemrev.0c00199","article-title":"Antifungal drug resistance: Molecular mechanisms in Candida albicans and beyond","volume":"121","author":"Lee","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2023.114874_b0190","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000221854","article-title":"Mode of action of 5-fluorocytosine and mechanisms of resistance","volume":"21","author":"Polak","year":"1975","journal-title":"Chemotherapy"},{"key":"10.1016\/j.addr.2023.114874_b0195","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1128\/CMR.12.4.501","article-title":"Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance","volume":"12","author":"Ghannoum","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.addr.2023.114874_b0200","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41467-019-13890-z","article-title":"5-fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus","volume":"11","author":"Billmyre","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.114874_b0205","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","article-title":"Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial","volume":"363","author":"Brouwer","year":"2004","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.addr.2023.114874_b0210","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1039\/C9CS00556K","article-title":"A comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promise","volume":"49","author":"Howard","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2023.114874_b0215","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.abd6919","article-title":"A marine microbiome antifungal targets urgent-threat drug-resistant fungi","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114874_b0220","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.copbio.2021.02.001","article-title":"Antifungal natural products","volume":"69","author":"Heard","year":"2021","journal-title":"Curr. Opin. Biotech."},{"key":"10.1016\/j.addr.2023.114874_b0225","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nchembio.2165","article-title":"Dual action antifungal small molecule modulates multidrug efflux and TOR signaling","volume":"12","author":"Shekhar-Guturja","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2023.114874_b0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.trsl.2022.04.002","article-title":"A dual action small molecule enhances azoles and overcomes resistance through co-targeting Pdr5 and Vma1","volume":"247","author":"Liu","year":"2022","journal-title":"Transl. Res."},{"key":"10.1016\/j.addr.2023.114874_b0235","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1073\/pnas.69.1.196","article-title":"Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism)","volume":"69","author":"Medoff","year":"1972","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2023.114874_b0245","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1126\/science.177.4050.709","article-title":"Amphotericin-B potentiation of rifampicin as an antifungal agent against yeast phase of Histoplasma Capsulatum","volume":"177","author":"Kobayashi","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114874_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106394","article-title":"Artemisinin elevates ergosterol levels of Candida albicans to synergise with amphotericin B against oral candidiasis","volume":"58","author":"Zhu","year":"2021","journal-title":"Int. J. Antimicrob. Ag."},{"key":"10.1016\/j.addr.2023.114874_b0255","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1038\/s41467-022-31308-1","article-title":"Targeting fungal membrane homeostasis with imidazopyrazoindoles impairs azole resistance and biofilm formation","volume":"13","author":"Revie","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.114874_b0260","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1365-2230.2009.03698.x","article-title":"In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis","volume":"35","author":"Bueno","year":"2010","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.addr.2023.114874_b0265","doi-asserted-by":"crossref","first-page":"e02046","DOI":"10.1128\/AAC.02046-19","article-title":"Inhibiting fungal echinocandin resistance by small-molecule disruption of geranylgeranyltransferase type I activity","volume":"64","author":"Sun","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114874_b0270","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/AAC.05323-11","article-title":"Reshuffling of Aspergillus fumigatus cell wall components chitin and beta-glucan under the influence of caspofungin or nikkomycin Z alone or in combination","volume":"56","author":"Verwer","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114874_b0275","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41467-018-08248-w","article-title":"Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus","volume":"10","author":"Whitesell","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.114874_b0280","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1073\/pnas.0813394106","article-title":"Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease","volume":"106","author":"Cowen","year":"2009","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2023.114874_b0285","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.chom.2019.08.004","article-title":"Calcium-calmodulin-calcineurin signaling: A globally conserved virulence cascade in eukaryotic microbial pathogens","volume":"26","author":"Park","year":"2019","journal-title":"Cell Host Microb."},{"key":"10.1016\/j.addr.2023.114874_b0290","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01397-07","article-title":"Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms","volume":"52","author":"Uppuluri","year":"2008","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.addr.2023.114874_b0295","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1128\/AAC.47.3.956-964.2003","article-title":"Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei","volume":"47","author":"Onyewu","year":"2003","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.addr.2023.114874_b0300","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1128\/EC.00310-10","article-title":"Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis","volume":"10","author":"Chen","year":"2011","journal-title":"Eukaryot. Cell"},{"key":"10.1016\/j.addr.2023.114874_b0305","doi-asserted-by":"crossref","first-page":"e00765","DOI":"10.1128\/mBio.00765-13","article-title":"Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo","volume":"5","author":"Butts","year":"2014","journal-title":"MBio"},{"key":"10.1016\/j.addr.2023.114874_b0310","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/femsre\/fux051","article-title":"Protein kinase C in fungi-more than just cell wall integrity","volume":"42","author":"Heinisch","year":"2018","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.addr.2023.114874_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001069","article-title":"PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90","volume":"6","author":"LaFayette","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2023.114874_b0320","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1365-2958.2007.05588.x","article-title":"The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans","volume":"63","author":"Munro","year":"2007","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.addr.2023.114874_b0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006350","article-title":"Metal chelation as a powerful strategy to probe cellular circuitry governing fungal drug resistance and morphogenesis","volume":"12","author":"Polvi","year":"2016","journal-title":"PLoS Genet."},{"key":"10.1016\/j.addr.2023.114874_b0330","doi-asserted-by":"crossref","first-page":"636834","DOI":"10.3389\/fcimb.2021.636834","article-title":"Transcriptomic and metabolomic analysis revealed roles of Yck2 in carbon metabolism and morphogenesis of Candida albicans","volume":"11","author":"Liboro","year":"2021","journal-title":"Front. Cell Infect. Mi."},{"key":"10.1016\/j.addr.2023.114874_b0335","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.chembiol.2019.12.008","article-title":"Overcoming fungal echinocandin resistance through inhibition of the non-essential stress kinase Yck2","volume":"27","author":"Caplan","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.addr.2023.114874_b0340","doi-asserted-by":"crossref","first-page":"e00399","DOI":"10.1128\/AAC.00399-19","article-title":"Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside","volume":"63","author":"Aruanno","year":"2019","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.addr.2023.114874_b0345","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1021\/acs.jmedchem.2c00595","article-title":"Development of lipo-gamma-AA peptides as potent antifungal agents","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114874_b0350","doi-asserted-by":"crossref","first-page":"106583","DOI":"10.1155\/2012\/106583","article-title":"Potent antifungal activity of pure compounds from traditional chinese medicine extracts against six oral Candida species and the synergy with fluconazole against azole-resistant candida albicans","volume":"2012","author":"Yan","year":"2012","journal-title":"Evid-Based Compl Alt"},{"key":"10.1016\/j.addr.2023.114874_b0355","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1007\/s00018-013-1260-1","article-title":"Properties and mechanisms of action of naturally occurring antifungal peptides","volume":"70","author":"van der Weerden","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.addr.2023.114874_b0360","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3390\/pharmaceutics13101589","article-title":"Antifungal activity of linear and disulfide-cyclized ultrashort cationic lipopeptides alone and in combination with fluconazole against vulvovaginal Candida spp.","volume":"13","author":"Czechowicz","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2023.114874_b0365","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00439-22","article-title":"Development of antifungal peptides against Cryptococcus neoformans; leveraging knowledge about the cdc50 delta mutant susceptibility for lead compound development","volume":"10","author":"Tancer","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.addr.2023.114874_b0370","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/jam.12737","article-title":"Synergistic activity of magnolol with azoles and its possible antifungal mechanism against Candida albicans","volume":"118","author":"Sun","year":"2015","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.addr.2023.114874_b0375","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/myc.13203","article-title":"Alternative treatment of fungal infections: Synergy with non-antifungal agents","volume":"64","author":"Rossato","year":"2021","journal-title":"Mycoses"},{"key":"10.1016\/j.addr.2023.114874_b0380","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jac\/dki264","article-title":"Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry","volume":"56","author":"Pina-Vaz","year":"2005","journal-title":"J Antimicrob Chemoth"},{"key":"10.1016\/j.addr.2023.114874_b0385","doi-asserted-by":"crossref","first-page":"e01921","DOI":"10.1128\/AAC.01921-19","article-title":"Identification of off-patent drugs that show synergism with amphotericin B or that present antifungal action against Cryptococcus neoformans and Candida spp.","volume":"64","author":"Rossi","year":"2020","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.addr.2023.114874_b0390","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/jof7020113","article-title":"Techniques for the assessment of in vitro and in vivo antifungal combinations","volume":"7","author":"Bidaud","year":"2021","journal-title":"J. Fungi"},{"key":"10.1016\/j.addr.2023.114874_b0395","doi-asserted-by":"crossref","first-page":"e3000856","DOI":"10.1371\/journal.pbio.3000856","article-title":"CombiANT: Antibiotic interaction testing made easy","volume":"18","author":"Fatsis-Kavalopoulos","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.addr.2023.114874_b0400","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/13693780701644140","article-title":"Animal models: an important tool in mycology","volume":"45","author":"Capilla","year":"2007","journal-title":"Med. Mycol."},{"key":"10.1016\/j.addr.2023.114874_b0405","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/01.qco.0000235163.70678.59","article-title":"Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions","volume":"19","author":"Clemons","year":"2006","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.addr.2023.114874_b0410","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4161\/viru.2.6.18520","article-title":"Drosophila and Galleria insect model hosts New tools for the study of fungal virulence, pharmacology and immunology","volume":"2","author":"Lionakis","year":"2011","journal-title":"Virulence"},{"key":"10.1016\/j.addr.2023.114874_b0415","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/microorganisms8030390","article-title":"Galleria mellonella for the evaluation of antifungal efficacy against medically important fungi, a narrative review","volume":"8","author":"Jemel","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.addr.2023.114874_b0420","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cell.2006.06.040","article-title":"Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast","volume":"126","author":"Parsons","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.addr.2023.114874_b0425","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1371\/journal.ppat.0030092","article-title":"Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans","volume":"3","author":"Xu","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2023.114874_b0430","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.cell.2014.10.044","article-title":"Unraveling the biology of a fungal meningitis pathogen using chemical genetics","volume":"159","author":"Brown","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.addr.2023.114874_b0435","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/msb.2011.31","article-title":"Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole","volume":"7","author":"Spitzer","year":"2011","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.addr.2023.114874_b0440","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/msb.2011.71","article-title":"Systematic exploration of synergistic drug pairs","volume":"7","author":"Cokol","year":"2011","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.addr.2023.114874_b0445","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cels.2015.12.003","article-title":"Prediction of synergism from chemical-genetic interactions by machine learning","volume":"1","author":"Wildenhain","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.addr.2023.114874_b0450","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54160","article-title":"Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections","volume":"9","author":"Wambaugh","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.addr.2023.114874_b0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009005","article-title":"Functional information from clinically-derived drug resistant forms of the Candida glabrata Pdr1 transcription factor","volume":"16","author":"Simonicova","year":"2020","journal-title":"PLoS Genet"},{"key":"10.1016\/j.addr.2023.114874_b0460","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nature16963","article-title":"Inhibiting fungal multidrug resistance by disrupting an activator-mediator interaction","volume":"530","author":"Nishikawa","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.114874_b0465","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/acs.jmedchem.9b00826","article-title":"Design and synthesis of fungal-selective resorcylate aminopyrazole Hsp90 inhibitors","volume":"63","author":"Huang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114874_b0470","doi-asserted-by":"crossref","first-page":"e01584","DOI":"10.1128\/AAC.01584-20","article-title":"Efg1 and Cas5 orchestrate cell wall damage response to caspofungin in Candida albicans","volume":"65","author":"Xiong","year":"2021","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.addr.2023.114874_b0475","doi-asserted-by":"crossref","first-page":"e00305","DOI":"10.1128\/AAC.00305-17","article-title":"Combination therapy with isavuconazole and micafungin for treatment of experimental invasive pulmonary aspergillosis","volume":"61","author":"Petraitis","year":"2017","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.addr.2023.114874_b0480","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/jac\/dkab233","article-title":"Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis","volume":"76","author":"Gebremariam","year":"2021","journal-title":"J. Antimicrob. Chemoth."},{"key":"10.1016\/j.addr.2023.114874_b0485","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00380-22","article-title":"The combination treatment of fosmanogepix and liposomal amphotericin B is superior to monotherapy in treating experimental invasive mold infections","volume":"66","author":"Gebremariam","year":"2022","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.addr.2023.114874_b0490","doi-asserted-by":"crossref","first-page":"e02429","DOI":"10.1128\/AAC.02429-19","article-title":"Combination therapy with ibrexafungerp (Formerly SCY-078), a first-in-class triterpenoid inhibitor of (1 -> 3)-beta-D-glucan synthesis, and isavuconazole for treatment of experimental invasive pulmonary aspergillosis","volume":"64","author":"Petraitis","year":"2020","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.addr.2023.114874_b0495","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12281-020-00369-4","article-title":"Combination therapy for invasive fungal infections","volume":"14","author":"Livengood","year":"2020","journal-title":"Curr. Fungal Infect. R."},{"key":"10.1016\/j.addr.2023.114874_b0500","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal combinations for treatment of cryptococcal meningitis in Africa","volume":"378","author":"Molloy","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114874_b0505","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMc1305981","article-title":"Combination antifungal therapy for Cryptococcal meningitis","volume":"368","author":"Loyse","year":"2013","journal-title":"New Engl. J. Med."},{"issue":"2016","key":"10.1016\/j.addr.2023.114874_b0510","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2023.114874_b0515","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis A randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2023.114874_b0520","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41564-019-0357-1","article-title":"Drug repurposing for antimicrobial discovery","volume":"4","author":"Farha","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.addr.2023.114874_b0525","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1172\/JCI32338","article-title":"The iron chelator deferasirox protects mice from mucormycosis through iron starvation","volume":"117","author":"Ibrahim","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2023.114874_b0530","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The deferasirox-ambisome therapy for mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J. Antimicrob. Chemoth."},{"key":"10.1016\/j.addr.2023.114874_b0535","article-title":"Combination therapy in Mucormycosis: Current evidence from the world literature, a mini review","volume":"33","author":"Meena","year":"2023","journal-title":"J. Mycolog. Medic."},{"key":"10.1016\/j.addr.2023.114874_b0540","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1128\/AAC.00212-12","article-title":"The Antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections","volume":"56","author":"Zhai","year":"2012","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.addr.2023.114874_b0545","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1473-3099(16)00074-8","article-title":"Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study","volume":"16","author":"Rhein","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2023.114874_b0550","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1473-3099(19)30127-6","article-title":"Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial","volume":"19","author":"Rhein","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2023.114874_b0555","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.68929","article-title":"An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis","volume":"10","author":"Ngan","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.addr.2023.114874_b0560","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.drudis.2022.04.006","article-title":"Machine learning to design antimicrobial combination therapies: Promises and pitfalls","volume":"27","author":"Cantrell","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2023.114874_b0565","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-018-0278-9","article-title":"Species-specific activity of antibacterial drug combinations","volume":"559","author":"Brochado","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.114874_b0570","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1128\/AAC.48.3.693-715.2004","article-title":"Combination antifungal therapy","volume":"48","author":"Johnson","year":"2004","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.addr.2023.114874_b0575","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2017.09.015","article-title":"Nanoparticle-based local antimicrobial drug delivery","volume":"127","author":"Gao","year":"2018","journal-title":"Adv. Drug Deliver. Rev."},{"key":"10.1016\/j.addr.2023.114874_b0580","doi-asserted-by":"crossref","first-page":"114078","DOI":"10.1016\/j.addr.2021.114078","article-title":"Overcoming the rising incidence and evolving mechanisms of antibiotic resistance by novel drug delivery approaches - An overview","volume":"181","author":"Lai","year":"2022","journal-title":"Adv. Drug Deliver. Rev."},{"key":"10.1016\/j.addr.2023.114874_b0585","doi-asserted-by":"crossref","first-page":"114502","DOI":"10.1016\/j.addr.2022.114502","article-title":"Strategies and progresses for enhancing targeted antibiotic delivery","volume":"189","author":"Nazli","year":"2022","journal-title":"Adv. Drug Deliver. Rev.,"},{"key":"10.1016\/j.addr.2023.114874_b0590","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2023.114874_b0595","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jac\/dkz041","article-title":"Diagnosis and treatment of invasive fungal infections: looking ahead","volume":"74","author":"Sanguinetti","year":"2019","journal-title":"J. Antimicrob. Chemoth."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23001898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23001898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:38:20Z","timestamp":1759210700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X23001898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":118,"alternative-id":["S0169409X23001898"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2023.114874","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New antifungal strategies: Drug combination and co-delivery","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2023.114874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114874"}}